Posted by Michael Wonder on 23 Feb 2023
Daratumumab in combination with lenalidomide and dexamethasone for the first-line treatment of patients with multiple myeloma when stem cell transplantation is unsuitable
22 February 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use of daratumumab in combination with lenalidomide and dexamethasone in the NHS in England.
For the time being, daratumumab, when used in combination with lenalidomide and dexamethasone, is not recommended for the first-line treatment of adults with multiple myeloma when autologous stem cell transplantation is unsuitable.
